These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 14612274

  • 1. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine.
    Yang DH, Liang WF, Xie YJ, Zhao NF, Fan J.
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274
    [Abstract] [Full Text] [Related]

  • 2. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF, Yang DH, Shen YH, Xie YJ, Zhao NF.
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [Abstract] [Full Text] [Related]

  • 3. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M.
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [Abstract] [Full Text] [Related]

  • 4. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
    Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, Esteban R, Guardia J.
    J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
    [Abstract] [Full Text] [Related]

  • 5. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP, Wo JE, Chen Z, Chen F, Liang WF, Liu KZ.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [Abstract] [Full Text] [Related]

  • 6. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H.
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
    Woo HY, Park H, Kim BI, Jeon WK, Cho YK, Kim YJ.
    Antivir Ther; 2007 Jun; 12(1):7-13. PubMed ID: 17503742
    [Abstract] [Full Text] [Related]

  • 11. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R.
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [Abstract] [Full Text] [Related]

  • 12. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U, Ural O, Findik D.
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [Abstract] [Full Text] [Related]

  • 13. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
    Ramezani A, Velayati AA, Roshan MR, Gachkar L, Banifazl M, Keyvani H, Aghakhani A.
    Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
    [Abstract] [Full Text] [Related]

  • 14. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B, Wei L, Chen M, Wang L.
    Microbiol Res; 2008 May; 163(4):487-92. PubMed ID: 17317127
    [Abstract] [Full Text] [Related]

  • 15. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler.
    Whalley SA, Brown D, Teo CG, Dusheiko GM, Saunders NA.
    J Clin Microbiol; 2001 Apr; 39(4):1456-9. PubMed ID: 11283071
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 Apr; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

  • 20. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL.
    Hepatology; 1996 Sep; 24(3):714-7. PubMed ID: 8781348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.